(EMAILWIRE.COM, July 17, 2009 ) Boca Raton, FL --- Pharmaceutical and consumer goods companies are often at the mercy of the microbial contamination testing of their products, costing them time and money.

Celsis shares with us how their Rapid Detection System is helping customers reduce inventory, reduce manufacturing cycle times and free up working capital.

“Manufacturing management should be looking at the cost of testing in terms of time and bottom-line
impact, rather than the cost of the test itself. Increasingly, companies around the world are using
Celsis Rapid Detection systems to cut days out of their production processes--which frees up working
capital and gets their products to market faster.” – Jay LeCoque, CEO, Celsis International plc

JL Haber, Vice President of Programming for Multi Media Productions, added “Celsis is an exciting company with a unique mission. We are excited to have them as a guest on our program.”
About Celsis
Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas; rapid detection, analytical and drug development services and ADME-Tox in vitro technologies. The company is listed on the London Stock Exchange (CEL.L).
Each division of Celsis International plc has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market. Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical and biopharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing. Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical and biotechnology industries. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver.
For more information, visit www.celsis.com

About 21st Century Business
21st Century Business airs on Fox Business Network (as paid programming) and DirecTV (as paid programming). 21st Century Business may also be viewed through video on demand via www.21cbtv.com. The 21CBTV Series is also available at more than 90 prestigious college universities, including Carnegie Mellon University, Howard University, Dartmouth College and Georgetown University.

For specific market-by-market air dates and times, please e-mail Moniqueh@mmpusa.com. For more information, please visit www.21cbtv.com.

- ##### -

Contact Information:
MultiMedia Productions
Gila Stern
Tel: 561-988-9449 x228
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.